Procurement Summary
Country : USA
Summary : Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Deadline : 17 Apr 2025
Other Information
Notice Type : Tender
TOT Ref.No.: 116901949
Document Ref. No. : HT9402-25-Q-9203
Competition : ICB
Financier : Self Financed
Purchaser Ownership : Public
Tender Value : Refer Document
Purchaser's Detail
Name :Login to see tender_details
Address : Login to see tender_details
Email : Login to see tender_details
Login to see detailsTender Details
Description
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: The following May 2025 newly approved drugs will be reviewed:
a. Alhemo - Antihemophilic Factors - Non-Factor Agentsb. Gomekli - Oncological Agents - N/Ac. Inzirqo - Diuretics - N/Ad. Otulfi - Targeted Immunomodulatory Biologics - Interleukin 23e. Pyzchiva - Targeted Immunomodulatory Biologics - Interleukin 23f. Raldesy - Antidepressants and non-opioid pain - Serotonin agonists and reuptake inhibitorg. Romvimza - Oncological Agents - N/Ah. Ustekinumab-ttwe - Targeted Immunomodulatory Biologics - Interleukin 23i. xromi - Oncological Agents - N/Aj. Zunveyl - Alzheimers Agents - N/A
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402...
Active Contract Opportunity
Notice ID : HT9402-25-Q-9203
Related Notice
Department/Ind. Agency : DEPT OF DEFENSE
Sub-tier : DEFENSE HEALTH AGENCY (DHA)
Office: DEFENSE HEALTH AGENCY
General Information
Contract Opportunity Type: Solicitation (Original)
Original Published Date: Mar 27, 2025 05:06 pm CDT
Original Date Offers Due: Apr 17, 2025 12:00 pm CDT
Inactive Policy: Manual
Original Inactive Date: Oct 17, 2025
Initiative: None
Classification
Original Set Aside:
Product Service Code: 6505 - DRUGS AND BIOLOGICALS
NAICS Code: 325412 - Pharmaceutical Preparation Manufacturing
Place of Performance: San Antonio, Tx 78230 USA
Documents
Tender Notice